SUN bioscience is setting the standard for organoid hardware technologies world-wide enabling next generation personalized drug development. Its flagship product, Gri3D®, features a customizable high-throughput hydrogel-based microwell platform to standardize organoids for compound screenings. Organoids are powerful human in vitro models for translational research and assessment of pharmaceutical efficacy and toxicity early on in drug development. These models have a higher predictive value compared to laboratory animals and conventional cell culture models. Gri3D® is fit for a very large range of three-dimensional healthy or diseased organoid models. It is currently used in extensive applications, including patient-specific targeted therapy screening in cancer organoids, novel T-cell killing assay methodologies for immuno-oncology studies, toxicity assessment on gastrointestinal organoids, and transport studies on organoid-based blood-brain barrier model. Exploiting the power of its bioengineering technologies, SUN bioscience engages in partnered projects for novel in vitro model generation and up-scaling to enable drug development.
SUN bioscience is privately held and headquartered in Lausanne, Switzerland. It was founded in 2016 and has established a world-wide reputation as organoid experts thanks to its numerous scientific contributions and awards.
